Dr. Reddy’s Laboratories Ltd. closed Monday’s trading session up more than 5% on the BSE, a sharp reversal after a year-to-date slide of 3%. The trigger was the Q2 FY27 filing, which showed an EBITDA margin of 20.6%, a massive beat against the street’s consensus of roughly 16%. This margin recovery was the highlight, masking a grim top-line where revenue fell 1.5% to ₹8,671 crore and net profit plunged 36% to ₹913.4 crore. EBITDA itself dropped 24.2% to ₹1,783 crore, yet the efficiency gains in costs and mix change were enough to excite traders.
The geographic breakdown tells a story of divergence. In the US, sales hit $260 million, buoyed by the launch of bosutinib (cancer) and sugammadex (neuromuscular reversal). The US base business grew at a double-digit pace. India, meanwhile, delivered 17% year-on-year growth to ₹1,850.8 crore, outperforming the expected 14-15% range. However, the margin contraction from 26.7% a year ago to 20.6% remains a structural concern for long-term holders, even if the absolute number surprised to the upside.
Brokerages are split on the sustainability of this margin pop. JPMorgan, which had held an Underweight rating for nearly four years, moved to Neutral with a ₹1,270 target. They noted adjusted core margins of 19.5% exceeded forecasts by 160 basis points, driven by R&D spending 100-200 bps below normal and a 12% drop in the low-margin services business. But they warned that the stock trades at 24x FY28 earnings, leaving little room for error. Kotak Institutional Equities remains bearish with a 'Reduce' rating and ₹1,220 target, arguing that while margins are recovering (19.1% adjusted), the stock lacks near-term catalysts beyond the known pipeline.
The bullish camp sees more upside. Nomura maintains a 'Buy' with a ₹1,730 target, citing cost efficiencies and a better business mix. Citi also holds a 'Buy' at ₹1,510, noting adjusted EBITDA of ₹1,640 crore was 40% above their estimate. Both point to the upcoming pipeline as the real driver. Management expects to resume semaglutide supplies in Canada in November 2026. The big one is intravenous abatacept, a treatment for autoimmune conditions, with US approval expected in December 2026. JPMorgan estimates abatacept will account for 11% of FY28 earnings and 15% of FY29 earnings.
The forward path hinges on execution. Management projects IFRS EBITDA margins to stay above 20% in the second half of FY27. The key risks? Timing of the abatacept approval and the ramp-up speed of semaglutide. If these catalysts materialize as scheduled, the current valuation premium over peers like Cipla and Lupin might be justified. If they slip, the 24x FY28 multiple offers no cushion. For now, the market is pricing in hope, not certainty.